Annabel Samimy
Stock Analyst at Stifel
(4.50)
# 283
Out of 5,182 analysts
57
Total ratings
50%
Success rate
39.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Annabel Samimy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OCS Oculis Holding AG | Maintains: Buy | $40 → $50 | $27.48 | +81.95% | 3 | Mar 5, 2026 | |
| EOLS Evolus | Maintains: Buy | $20 → $17 | $5.33 | +218.95% | 2 | Jan 13, 2026 | |
| TRVI Trevi Therapeutics | Maintains: Buy | $15 → $18 | $13.87 | +29.78% | 1 | Dec 19, 2025 | |
| SUPN Supernus Pharmaceuticals | Maintains: Hold | $50 → $55 | $47.85 | +14.94% | 8 | Dec 19, 2025 | |
| RGNX REGENXBIO | Maintains: Buy | $40 → $45 | $9.12 | +393.42% | 3 | Dec 19, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $45 → $52 | $29.26 | +77.72% | 2 | Dec 19, 2025 | |
| MBX MBX Biosciences | Maintains: Buy | $45 → $50 | $29.78 | +67.90% | 2 | Dec 19, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $55 → $48 | $40.96 | +17.19% | 4 | Dec 19, 2025 | |
| LGND Ligand Pharmaceuticals | Maintains: Buy | $220 → $230 | $227.44 | +1.13% | 2 | Dec 10, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $50 → $90 | $42.21 | +113.22% | 2 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $87 → $145 | $126.84 | +14.32% | 3 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $2.82 | +538.30% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $17 | $4.97 | +242.05% | 4 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $8.21 | +119.24% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $12.01 | +99.83% | 1 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $80 | $30.00 | +166.67% | 6 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $225 → $230 | $202.72 | +13.46% | 8 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $0.94 | +2,453.19% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $700 → $750 | $2.07 | +36,131.88% | 3 | Apr 16, 2020 |
Oculis Holding AG
Mar 5, 2026
Maintains: Buy
Price Target: $40 → $50
Current: $27.48
Upside: +81.95%
Evolus
Jan 13, 2026
Maintains: Buy
Price Target: $20 → $17
Current: $5.33
Upside: +218.95%
Trevi Therapeutics
Dec 19, 2025
Maintains: Buy
Price Target: $15 → $18
Current: $13.87
Upside: +29.78%
Supernus Pharmaceuticals
Dec 19, 2025
Maintains: Hold
Price Target: $50 → $55
Current: $47.85
Upside: +14.94%
REGENXBIO
Dec 19, 2025
Maintains: Buy
Price Target: $40 → $45
Current: $9.12
Upside: +393.42%
Mineralys Therapeutics
Dec 19, 2025
Maintains: Buy
Price Target: $45 → $52
Current: $29.26
Upside: +77.72%
MBX Biosciences
Dec 19, 2025
Maintains: Buy
Price Target: $45 → $50
Current: $29.78
Upside: +67.90%
Apellis Pharmaceuticals
Dec 19, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $40.96
Upside: +17.19%
Ligand Pharmaceuticals
Dec 10, 2025
Maintains: Buy
Price Target: $220 → $230
Current: $227.44
Upside: +1.13%
Structure Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $50 → $90
Current: $42.21
Upside: +113.22%
Nov 24, 2025
Maintains: Buy
Price Target: $87 → $145
Current: $126.84
Upside: +14.32%
Jan 8, 2025
Initiates: Buy
Price Target: $18
Current: $2.82
Upside: +538.30%
Nov 22, 2024
Maintains: Buy
Price Target: $20 → $17
Current: $4.97
Upside: +242.05%
Jul 3, 2024
Initiates: Buy
Price Target: $18
Current: $8.21
Upside: +119.24%
May 3, 2024
Initiates: Buy
Price Target: $24
Current: $12.01
Upside: +99.83%
Mar 15, 2024
Reiterates: Buy
Price Target: $80
Current: $30.00
Upside: +166.67%
Mar 15, 2024
Maintains: Buy
Price Target: $225 → $230
Current: $202.72
Upside: +13.46%
Aug 24, 2021
Initiates: Buy
Price Target: $24
Current: $0.94
Upside: +2,453.19%
Apr 16, 2020
Maintains: Buy
Price Target: $700 → $750
Current: $2.07
Upside: +36,131.88%